Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Poor sleep in patients with multiple sclerosis.
[Plasmapheresis in central nervous system disorders].
BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)
Modulation of nitric oxide synthase by arginase and methylated arginines during the acute phase of experimental multiple sclerosis.
Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro.
RILUTEK®
Motor skill learning requires active central myelination.
Centocor briefing document for Ustekinumab, submitted to FDA
Increased PK11195 PET binding in the cortex of patients with MS correlates with disability.
Activation of axonal Kv7 channels in human peripheral nerve by flupirtine but not placebo - therapeutic potential for peripheral neuropathies: results of a randomised controlled trial.
Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis.
Oral Laquinimod for Multiple Sclerosis Granted Fast Track Status by FDA
Peripheral accumulation of newly produced T and B lymphocytes in natalizumab-treated multiple sclerosis patients.
The epidemiology of multiple sclerosis in Latin America and the Caribbean: a systematic review.
Biogen Idec announces positive top-line results from Phase 3 study of peginterferon beta-1a in multiple sclerosis
Apitope Announces Positive Results from Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis
Durable pharmacological responses from the peptide drug ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease.
BTG Commences Phase IIa Study of Multiple Sclerosis
IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).
Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis.
Combined central and peripheral demyelination: Clinical features, diagnostic findings, and treatment.
4-Aminopyridine ameliorates mobility but not disease course in an animal model of multiple sclerosis.
Increased axonal expression of nectin-1 in multiple sclerosis plaques.
Current recommendations for multiple sclerosis treatment in pregnancy and puerperium.
Idiopathic aquaporin-4 antibody negative longitudinally extensive transverse myelitis.

Pages